Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences

Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). A...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Asger, Korsholm, Kasper, Mellemkjær, Søren, Nielsen-Kudsk, Jens Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476463/
https://www.ncbi.nlm.nih.gov/pubmed/28652963
http://dx.doi.org/10.1016/j.rmcr.2017.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476463/
https://www.ncbi.nlm.nih.gov/pubmed/28652963
http://dx.doi.org/10.1016/j.rmcr.2017.06.005

Ejemplares similares